

1 STATE OF OKLAHOMA

2 2nd Session of the 55th Legislature (2016)

3 HOUSE BILL 2607

By: McDaniel (Jeannie)

4  
5  
6 AS INTRODUCED

7 An Act relating to public safety; amending 63 O.S.  
8 2011, Section 1-533, which relates to an education  
9 and newborn screening program; requiring State Board  
of Health to expand program to include  
adrenoleukodystrophy; and providing an effective  
date.

10  
11  
12 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

13 SECTION 1. AMENDATORY 63 O.S. 2011, Section 1-533, is  
14 amended to read as follows:

15 Section 1-533. A. The State Board of Health shall provide,  
16 pursuant to the provisions of Section 1-534 of this title as  
17 technologies and funds become available, an intensive educational  
18 and newborn screening program among physicians, hospitals, public  
19 health nurses, and the public concerning phenylketonuria, related  
20 inborn metabolic disorders, and other genetic or biochemical  
21 disorders for which:

22 1. Newborn screening will provide early treatment and  
23 management opportunities that might not be available without  
24 screening; and

1           2. Treatment and management will prevent mental retardation  
2 and/or reduce infant morbidity and mortality.

3           B. This educational and newborn screening program shall include  
4 information about:

5           1. The nature of the diseases;

6           2. Examinations for the detection of the diseases in infancy;  
7 and

8           3. Follow-up measures to prevent the morbidity and mortality  
9 resulting from these diseases.

10          C. For purposes of this section, "phenylketonuria" means an  
11 inborn error of metabolism attributable to a deficiency of or a  
12 defect in phenylalanine hydroxylase, the enzyme that catalyzes the  
13 conversion of phenylalanine to tyrosine. The deficiency permits the  
14 accumulation of phenylalanine and its metabolic products in the body  
15 fluids. The deficiency can result in mental retardation  
16 (phenylpyruvic oligophrenia), neurologic manifestations (including  
17 hyperkinesia, epilepsy, and microcephaly), light pigmentation, and  
18 eczema. The disorder is transmitted as an autosomal recessive trait  
19 and can be treated by administration of a diet low in phenylalanine.

20          D. As funds become available, the State Board of Health shall  
21 expand the educational and newborn screening program set forth in  
22 subsection A of this section to include screening for  
23 adrenoleukodystrophy (ALD).  
24

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

E. The State Board of Health shall promulgate any rules  
necessary to effectuate the provision of this section.

SECTION 2. This act shall become effective November 1, 2018.

55-2-7988 AM 12/09/15